预防性玻璃体腔注射5-氟尿嘧啶和肝素预防高危视网膜脱离患者增生性玻璃体视网膜病变:随机对照试验研究方案
本研究为随机双盲对照多中心试验,拟纳入560例原发性孔源性视网膜脱离的高危患者,比较术中玻璃体腔灌注5-氟尿嘧啶联合低分子肝素与平衡盐溶液的疗效,主要终点为12周内PVR grade CP 1及以上发生率,假设对照组发生率为35%,预期降低三分之一。
要点
- 高危PVR患者通过激光 flare 光度测定法无创评估。
- 术中经眼内灌注给予5-FU和LMWH,对照组用平衡盐溶液。
- 主要终点为12周内PVR grade CP 1及以上发生率。
核心结论
- 该试验旨在验证术中预防性使用5-FU和LMWH能否降低高危原发性孔源性视网膜脱离患者PVR的发生率。
研究设计与样本
- 随机、双盲、对照、多中心、干预性试验,包含一次期中分析。
- 计划样本量560例(每组280例),按5%脱落率调整,把握度80%。
主要发现
- 基于既往发表结果假设对照组PVR grade CP 1发生率为35%,降低三分之一视为临床相关。
关键数值与推荐
- 主要终点:治疗后12周内发生PVR grade CP 1或更高。
- 次要终点:PVR grade CA、最佳矫正视力、视网膜复位手术次数和范围、药物相关不良事件。
临床怎么用
- 在常规玻璃体切割术中经眼内灌注给予5-FU和LMWH作为预防性治疗。
- 使用激光 flare 光度测定法无创筛选PVR高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proliferative vitreoretinopathy (PVR) is the major cause for postoperative failure after vitreo-retinal surgery for primary rhegmatogenous retinal detachment (RRD). Adjunct pharmaceutical therapy was found to be ineffective once PVR is established. Preliminary data suggest that prevention of PVR yields better functional outcome. So far, there is no standard therapy to prevent PVR. METHODS/DESIGN: This is a randomized, double-blind, controlled, multicenter, interventional trial with one interim analysis. High-risk patients for PVR with primary RRD will be allocated equally to the following treatment arms: (a) verum: intraoperative adjuvant application of 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) and (b) placebo: routinely used intraocular infusion with balanced salt solution during routine PPV. PVR risk is assessed by non-invasive aqueous flare measurement by using laser flare photometry. The primary endpoint of the trial is the occurrence of PVR grade CP (C: full-thickness retinal folds or subretinal strands in clock hours; P: located posterior to equator) 1 or higher within 12 weeks after treatment. Secondary endpoints include PVR grade CA (A: located anterior to equator), best corrected visual acuity, number and extent of surgical procedures to achieve retinal re-attachment, and occurrence of drug-related adverse events within 12 weeks. It is assumed, on the basis of previously published results, that the incidence of PVR grade CP 1 is 35% in the control group and that a reduction by one third would be clinically relevant. Given the sequential design and adjustment for a dropout rate of 5%, a total sample size of 560 patients (280 per group) was calculated to ensure a power of 80% for the confirmatory analysis. DISCUSSION: The present trial uses intraoperative intravitreal 5-FU and LMWH as a prophylactic therapy in high-risk patients with primary RRD, aiming to reduce the incidence of PVR in the group that receives the trial drug. Using laser flare photometry to identify high-risk patients for PVR, this trial will test the effectiveness of a simple treatment to prevent PVR. TRIAL REGISTRATION: EudraCT no.: 2015-004731-12, registered October 21, 2015; ClinicalTrials.gov Identifier: NCT02834559 , registered July 12, 2016. Protocol version: Version 02. Date: September 18, 2016.
引用
- Schaub F, Hoerster R, Schiller P, et al. Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial. Trials. 2018. PMID: 30012187. doi:10.1186/s13063-018-2761-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。